BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately

BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately

BioSig Technologies, Inc. (NASDAQ: BSGM) or ("BioSig" or "the Company"), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer ("CEO"), effective immediately.  Additionally, Mr. Amato will serve on the Company's Board of Directors, which is currently being assembled.  Recall, that on April 4, 2024, the Company announced the engagement of Consulting firm, Bridge Associates International Pharmaceutical Consulting ("BAIPC"), led by Mr. Amato.  This corporate action was the natural progression as the Company continues to realize meaningful progress towards its goals of both resorting and creating lasting shareholder value.

Commenting on his appointment as CEO of BioSig, Mr. Amato expressed, "Approximately 2 months ago, I took the initiative to review, analyze, and address the urgent issues that had the potential to negatively impact the Company's future. Since then, important and material progress has been realized on multiple fronts, and I have accepted this new position to accelerate the implementation of the comprehensive turnaround strategy.  The Company believes that there is substantial value to be unlocked through its current assets including its core product line, PURE EP™. We will continue to add the appropriate team to reach our goals. I wish to thank our many loyal shareholders and reiterate my unwavering commitment to both restore and create shareholder value."

The Company will continue to update shareholders as additional material event(s) occur.

Personal Bio, Mr. Anthony Amato - Age 56

Anthony Amato is a business leader and entrepreneurial thinker with an intuitive ability to rapidly assess challenges and identify growth opportunities. He quickly sees organizational vision and understands goals, taking appropriate ownership and action required to guide the team, achieving aggressive targets and performance levels. He has outstanding interpersonal, business development, team building and management skills. Anthony has hands-on executive skills at engaging and influencing key stakeholders to not only grow business but also to optimize profits.

Mr. Amato founded InQuest Science in March 2017 and then acquired Bridge Associates International Pharmaceutical Consulting in March 2020. He is the former Director of Sales for Mesa Labs in Denver CO, a Nasdaq listed corporation that specializes in providing quality control products and services to ensure the safety and efficacy of equipment used in hospitals, pharmaceutical, medical device manufacturers, blood banks, laboratories, pharmacies, and industrial facilities.

In July of 1999, he founded Amega Scientific Corporation. He grew the company from a start-up operation to a worldwide industry leader. Anthony developed and managed a staff throughout North America, establishing R&D, production, logistics, administration and sales. Clients included pharmaceutical, biotech, hospitals, government facilities, and research universities. Amega Scientific was the leading innovator in the Environmental Monitoring System industry. Amega Scientific was an ISO 17025 corporation instituting GxP requirements. Amega Scientific was acquired by Mesa Labs (MLAB) in November 2013.

Mr. Amato graduated from Glassboro State College in New Jersey in 1989, with a dual degree in business management and finance.

About BioSig Technologies, Inc. (NASDAQ: BSGM)

BioSig Technologies is a medical technology company focused on deciphering the body's electrical signals, starting with heart rhythms. By leveraging a first of its kind combination of hardware and software, we deliver unprecedented cardiac signal clarity, ending the reliance on ‘mixed signals' and ‘reading between the lines.' Our platform technology is addressing some of healthcare's biggest challenges—saving time, saving costs, and saving lives.

The Company's product, the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) BioSig's ability to regain compliance with and meet the continued listing requirements of the Nasdaq Capital Market to maintain listing of its common stock; (ii) our cost reduction plan and associated workforce reduction or other cost-saving measures not reaching the targeted reduction of cash burn by 50%; (iii) the geographic, social, and economic impact of pandemics or worldwide health issues on BioSig's ability to conduct its business and raise capital in the future when needed; (iv) BioSig's inability to manufacture its products and product candidates on a commercial scale on its own, or in collaboration with third parties; (v) difficulties in obtaining financing on commercially reasonable terms; (vi) changes in the size and nature of BioSig's competition; (vii) loss of one or more key executives or scientists; and (viii) difficulties in securing regulatory approval to market BioSig's products and product candidates. For a discussion of other risks and uncertainties, and other important factors, any of which could cause BioSig's actual results to differ from those contained in forward-looking statements, see BioSig's filings with the Securities and Exchange Commission ("SEC"), including the section titled "Risk Factors" in BioSig's Annual Report on Form 10-K, filed with the SEC on April 16, 2024. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise, except as required by law.


Todd Adler BioSig Technologies, Inc. Investor Relations 55 Greens Farms Rd Westport, CT 06880 tadler@biosigtech.com 203-409-5444 ext. 104 Or Anthony Amato, Chief Executive Officer aamato@biosigtech.com 203-409-5444 ext. 102 

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

BSGM
BioSig Technologies

BioSig Technologies Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BioSig Technologies

BioSig Technologies

Overview

BioSig Technologies (OTCQB:BSGM) is a medical device company that has developed a proprietary technology platform targeting the rapidly growing electrophysiology (EP) device market. EP devices are used in the treatment of cardiac arrhythmias, which can lead to stroke or even death. The current standard of care is cardiac catheter ablation which has a low efficacy rate.

BioSig Technologies’ goal is to bring to market an advanced biomedical signal processing technology that can address unmet needs for the treatments of challenging and chronic diseases such as arrhythmias. The company is advancing towards commercialization of its PURE EPTM System which is designed to improve the clarity of clinical signals available for EP studies and ablation procedures.

Bringing Next Gen EP Device to Market

BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.

BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig"), which recently merged with Streamex Exchange Corporation ("Streamex") (together, "BSGM" or the "Company"), announced today that it will change its name to Streamex Corp., effective at 12:01 am Eastern Time on Friday, September 12, 2025. In connection with the name change, the Company will change its trading symbol to "STEX." The Company's common stock will commence trading on the Nasdaq Capital Market exchange under the new name and trading symbol on September 12, 2025.

As of September 12, 2025, all Company stock trading, filings, and market related information will be reported under the new symbol "STEX". The Company's CUSIP number will remain unchanged, and no action is required from shareholders. No other aspects of the Company's corporate structure or operations are impacted by the ticker symbol change.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Monetary Metals Enters into Exclusive Partnership with Streamex  to Create Tokenized Yield-Bearing Gold Products

Monetary Metals Enters into Exclusive Partnership with Streamex to Create Tokenized Yield-Bearing Gold Products

Monetary Metals has signed an agreement with Streamex to provide yield on physical gold bullion with upwards of $1 billion USD in near term lease capacity

Monetary Metals, the pioneer in gold-and-silver-denominated fixed income products, has partnered with Streamex Exchange Corporation ("Streamex"), which recently merged with BioSig Technologies Inc. (Nasdaq: BSGM). Through this collaboration, Monetary Metals will gain exclusive rights to put Streamex's tokenized gold to work earning yield.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals

Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals

Partnership unlocks exclusive tokenization rights, a four percent (4%) annual yield target on physical bullion, revenue share tied to leasing volumes and the creation of a groundbreaking institutionalized asset providing yield on physical gold holdings

Key Partnership Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ: BSGM), today provided an update regarding the status of the merger and related proxy materials.

The merger transaction closed on May 28, 2025, under the previously executed Share Purchase Agreement. As part of this transaction, 19.99% of BioSig shares are already issuable to Streamex shareholders, with the remaining issuances pending Nasdaq approval.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Streamex  to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th

Streamex to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th

BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ: BSGM), a gold tokenization infrastructure company building the foundation for on-chain gold markets, today announced that it will participate in the 5 th annual Needham Virtual Crypto 1x1 Conference on September 4 th 2025. BioSig and Streamex CEO, Henry McPhie and CIO, Mitch Williams will host one on one meetings with institutional investors at the conference.

About Streamex

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioSig Technologies

BioSig Technologies Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News